Teva Pharmaceutical to Cut 14,000 Jobs - WSJ
Shares of generic drugmakers rise on hope that legal issues are nearing an end - MarketWatch
Teva Pharmaeutical Stock Gets Upgrade From Analyst | Barron's
Investors wary of Teva-Mylan merger - MarketWatch
Battered Teva Pharmaceutical Industries Ltd (ADR) Stock Still Is Toxic
The Valsartan Drug market research study provides critical information on the financial summary, shareholding patterns, and revenue mix of leading firms with a projected CAGR of 7.6%. - MarketWatch
Israel stocks rise, led by Teva, ICL - MarketWatch
Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO
Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Coming Back
Possible criminal probe undermines recovery in opioid stocks since global legal settlement announced - MarketWatch
Teva: This One Is Difficult (NYSE:TEVA) | Seeking Alpha
Teva shares surge on corporate shake-up - MarketWatch
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Teva Stock Has Crumbled, and Chairman Sol Barer Is Buying Up Shares | Barron's
Teva Pharmaceutical Is Bottoming: Here's My Strategy - RealMoney
Teva Stock Is Falling as an Analyst Says It Needs 'Numerous Litigation Wins' | Barron's
Teva Pharmaceuticals reports earnings on Wednesday. Here's what to expect - MarketWatch
How the price action of Teva Pharmaceutical (TEVA) is used to our Advantage - MarketWatch
Teva Stock Could Reach $100 | Barron's
Teva Pharmaceutical Is Bottoming: Here's My Strategy - RealMoney
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Announces Abstracts at the ACAAI Annual Scientific Meeting
TEVA | Teva Pharmaceutical Industries Ltd. ADR Stock Overview (U.S.: NYSE) | Barron's
